三友医疗(688085.SH)：公司与韩国细基生物株式会社签署战略合作和经销协议

Core Viewpoint - Company signed a strategic cooperation and distribution agreement with CGBIO for exclusive rights to market and distribute Novosis products in mainland China, enhancing its competitive position in the orthopedic biomaterials sector [1][2] Group 1: Agreement Details - The agreement grants the company exclusive, non-transferable rights for procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1] - The authorization is valid for six years from the date the products receive medical device registration from the Chinese regulatory authority [1] Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [1] - The product is produced using genetically engineered E. coli to efficiently manufacture rhBMP-2, which promotes new bone formation and has strong osteoconductive and osteoinductive properties [1] Group 3: Market Impact - The acquisition of exclusive distribution rights for Novosis will enrich the company's product line and enhance its offerings in the orthopedic biomaterials field [2] - This development is expected to provide comprehensive surgical solutions for patients and doctors, positively impacting the company's operations and overall competitiveness [2]